Drug Profile


Alternative Names: Dp4cycH4mT

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Sydney
  • Developer Collaborative Medicinal Development
  • Class Antineoplastics; Small molecules; Thiosemicarbazones
  • Mechanism of Action Cell death stimulants; Gene expression stimulants; Iron chelating agents; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Sep 2016 Chemical structure information added
  • 27 Sep 2016 Preclinical data in Cancer released by Collaborative Medicinal Development (Collaborative Medicinal Development website, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top